Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8034816 | 1.00 | DPP4 (0.46) | DPP4TSHRDPP7ALDH1A1MAPT | |
| SCHEMBL9965493 | 0.83 | DPP4 (0.35) | DPP4TSHRDPP7ALDH1A1MAPT | |
| SCHEMBL12908822 | 0.83 | ALDH1A1 (0.50) | DPP4TSHRDPP7ALDH1A1MAPT | |
| SCHEMBL19026679 | 0.80 | TSHR (0.35) | DPP4TSHRDPP7USP2MMP1 | |
| SCHEMBL19864496 | 0.80 | TSHR (0.35) | DPP4TSHRDPP7USP2MMP1 | |
| SCHEMBL23095553 | 0.80 | TSHR (0.35) | DPP4TSHRDPP7USP2MMP1 | |
| SCHEMBL32690449 | 0.79 | DPP7 (0.53) | DPP4DPP7USP2MMP2 | |
| SCHEMBL4126714 | 0.78 | DPP4 (0.43) | DPP4ALDH1A1MAPTPTGS1ARG1 | |
| SCHEMBL1337609 | 0.78 | USP2 (0.50) | DPP4TSHRDPP7ALDH1A1MAPT | |
| SCHEMBL12898741 | 0.78 | ALDH1A1 (0.50) | DPP4ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102596913-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2016-11-09 | — | — | CN | claimed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
| CN-102596913-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2016-11-09 | — | — | CN | disclosed |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP4 4359/4885TSHR 1095/4885DPP7 3990/4885 |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | DPP4 474/4885TSHR 357/4885DPP7 445/4885 |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | DPP4 474/4885TSHR 357/4885DPP7 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.